Latest Headlines

  1. Variational AI Enters Collaboration With Merck To Apply Generative AI To Drug Discovery 9/23/2025

    Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki platform to design and optimize novel small molecule candidates against two undisclosed targets.

  2. Kelun-Biotech's New Drug Application For Its Novel Next-Generation Selective RET Inhibitor A400/EP0031 Accepted For Review By The NMPA For The Treatment Of RET-fusion Positive NSCLC 9/22/2025

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).

  3. Scientists Find Potential New Drug Target For Psychiatric And Neurological Disorders 9/19/2025

    In a new National Institutes of Health-funded research report, scientists at Johns Hopkins Medicine say they have identified a potential target for drugs that could dial up or down the activity of certain brain proteins in efforts to treat psychiatric disorders, such as anxiety and schizophrenia, and a neurological condition that affects movement.

  4. FDA Grants Orphan Drug Designation To NS-051/NCNP-04 For The Treatment Of Duchenne Muscular Dystrophy 9/19/2025

    NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne) in patients amenable to exon 51 skipping.

  5. xFOREST Therapeutics And Axcelead DDP Launch Joint Research Initiative On RNA Structure-Targeted Small Molecule Drug Discovery 9/19/2025

    xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research collaboration aimed at developing RNA structure-targeted small molecule therapeutics for multiple diseases.

  6. New Drug Application For Gadoquatrane Accepted For Review In China 9/18/2025

    Bayer today announced that the Center of Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application for gadoquatrane.

  7. Anti-MTBR (Microtubule Binding Region) Tau Antibody Etalanetug Granted FDA Fast Track Designation 9/18/2025

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

  8. Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (CKD) 9/17/2025

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD).

  9. Rubedo Life Sciences Announces U.S. FDA Clearance Of IND For Selective GPX4 Modulating Lead Drug Candidate RLS-1496 For Actinic Keratosis, Expands Clinical Advisory Board 9/17/2025

    Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis.

  10. Adagene Expands SAFEbody® Collaboration And License Agreement With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate 9/16/2025

    Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.